Duke Street Bio Announces Appointment of Head of Clinical Operations
Duke Street Bio, a London based biotech focusing on the discovery of novel precision medicine-based cancer therapies, today strengthens its leadership team with the appointment of Jeff Thompson, PhD, MBA, as Head of Clinical Operations. Jeff brings a wealth of experience spanning over three decades in the Pharma and Biotech Industries, and has an impressive record of taking molecules from preclinical research through to clinical development.
Jeff obtained his BSc in Biochemistry from Liverpool Polytechnic, followed by a PhD in Cell Biology/Biochemistry at Victoria University of Manchester. Further complementing his scientific background, Jeff accomplished an MBA at Henley Management College.
Jeff most recently served as a Senior Director of Clinical Programs at AstraZeneca UK, where he successfully oversaw a portfolio of clinical studies for various oncology targets. Before AstraZeneca, he was the Vice President of Clinical Operations at Inflazome UK, where he led the operations to transition pre-clinical assets into clinical development. Under his leadership, Inflazome successfully navigated two assets through First in Human (FTIH) studies, contributing to the company’s acquisition by Roche in 2021. Jeff’s propensity for hands-on work in smaller, dynamic teams and his substantial experience in early phase development make him an ideal fit for Duke Street Bio.
“We are thrilled to welcome Jeff to the team” said Alan Wise, CEO of Duke Street Bio. “His depth of experience and his passion for small start-up Biotech will prove invaluable as we navigate the complex landscape of clinical development. His appointment comes at a pivotal time as we transition our novel PARP1-selective and PARP7 inhibitor programs into the clinic.”